Mixture Of Interferon Alpha 2B With Modified Sequences Thereof
Summary
PharmaEssentia Corporation filed USPTO patent application US20260109750A1 for interferon-polymer conjugates to treat three rare blood disorders: idiopathic myelofibrosis, polycythaemia vera, and essential thrombocythaemia. The application was submitted on October 17, 2025, listing six inventors including Ko-Chung Lin and Shin-Jye Lee. CPC classifications include C07K 14/56, C12P 21/02, G01N 33/6824, and A61K 38/00.
“This invention relates to use of interferon-polymer conjugates described in the specification to treat idiopathic myelofibrosis, polycythaemia vera and essential thrombocythaemia.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
PharmaEssentia Corporation filed patent application US20260109750A1 with the USPTO on October 17, 2025, covering interferon-polymer conjugates for treating idiopathic myelofibrosis, polycythaemia vera, and essential thrombocythaemia. The application names six inventors and includes CPC classifications relevant to protein conjugates and therapeutic applications.
This publication creates intellectual property rights for PharmaEssentia and may affect competitors developing treatments for these rare hematologic disorders. No immediate compliance obligations are imposed on parties outside the applicant.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Mixture Of Interferon Alpha 2B With Modified Sequences Thereof
Application US20260109750A1 Kind: A1 Apr 23, 2026
Assignee
PharmaEssentia Corporation
Inventors
Ko-Chung Lin, Ming-Pin Hsu, Yu-Kuei Tsai, Yi-Te Yo, Jiing-Guang Chuang, Shin-Jye Lee
Abstract
This invention relates to use of interferon-polymer conjugates described in the specification to treat idiopathic myelofibrosis, polycythaemia vera and essential thrombocythaemia.
CPC Classifications
C07K 14/56 C12P 21/02 G01N 33/6824 A61K 38/00
Filing Date
2025-10-17
Application No.
19361604
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.